Puma Biotechnology (PBYI) Operating Expenses (2010 - 2026)

Puma Biotechnology has reported Operating Expenses for 17 years, with the latest figure at $48.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 15.75% year-over-year to $48.6 million; the trailing twelve-month figure through Mar 2026 stood at $197.7 million (up 1.14% YoY), and the FY2025 full-year result was $191.1 million, down 4.23% from the prior year.
• Operating Expenses for Q1 2026 stood at $48.6 million, down from $58.3 million in the prior quarter.
• The five-year high for Operating Expenses was $58.5 million in Q3 2024, with the low at $42.0 million in Q1 2025.
• Historically, Operating Expenses has averaged $49.8 million across 5 years, with a median of $48.4 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses slumped 40.42% — and 2025, when it rose 27.64%.
• Puma Biotechnology's Operating Expenses stood at $55.7 million in 2022, then advanced by 3.09% to $57.4 million in 2023, then fell by 20.33% to $45.7 million in 2024, then grew by 27.64% to $58.3 million in 2025, then slipped by 16.63% to $48.6 million in 2026.
• The last three Operating Expenses figures came in at $48.6 million (Q1 2026), $58.3 million (Q4 2025), and $44.9 million (Q3 2025), per Business Quant data.